New Haven, Connecticut 06510

  • Head and Neck Squamous Cell Carcinoma

Purpose:

The purpose of this study is to assess the activity of 5-azacitidine in patients with Human Papilloma Virus (HPV)-positive and HPV- negative head and neck squamous cell carcinoma (HNSCC). The response activity will be determined by analyzing your tumor tissue prior to and after treatment with 5-azacitidine. Preliminary studies in mice bearing human head and neck cancers or head and neck cancer cells cultured in laboratories suggest that treatment with 5-azacitidine increases changes in cancer cells that lead to their death. This study is designed to determine if similar changes occur in cancer cells of patients with head and neck cancer. The study also aims to determine the amount of a specific type of protein, p53 before and after treatment. Research has shown that the p53 protein is associated with anti-tumor activity. Finally, this study is measuring the amount of a specific type of protein called interferon in your tumor tissue. Interferons are proteins made and released by the body in response to pathogens (disease causing agents) such as viruses, bacteria, or tumor cells. Interferons allow for communication between cells to trigger the protective defenses of the immune system that remove pathogens (disease causing agents) or tumors.


Study summary:

Primary Objectives: The primary objectives of this study are: • to determine the proportion of HPV-positive patients in whom 5-azacytidine increases APOBEC RNA expression. Secondary Objectives The secondary objectives of this study are: - to investigate response (proliferation, apoptosis), as well as reactivation of IFN pathways in patients treated with 5-azacitadine for HPV-positive and HPV-negative HNSCC. - to investigate the clinical activity of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC. - to investigate the safety of 5-azacitadine in patients with HPV-positive and HPV-negative HNSCC


Criteria:

Inclusion Criteria: 1. Histologically confirmed p16 or HPV PCR positive HNSCC with surgically resectable disease 2. Age ≥18 years of age. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2 4. ANC greater than or equal to 1500, Hb greater than or equal to 8, platelet count greater than or equal to 100,000 Exclusion Criteria: 1. AST or ALT greater than 2.5 x ULN 2. Known brain metastases 3. Women must not be pregnant or breastfeeding 4. Known allergy to 5-azacitadine 5. Patients receiving any other investigational agents within 4 weeks of starting the study


NCT ID:

NCT02178072


Primary Contact:

Principal Investigator
Barbara Burtness, MD
Yale University School of Medicine, Smilow Cancer Center at Yale New Haven Hospital, Yale Comprehens

Hari A Deshpande, MD
Phone: 203-200-4622
Email: hari.deshpande@yale.edu


Backup Contact:

Email: barbara.burtness@yale.edu
Barbara Burtness, MD
Phone: 203-737-7636


Location Contact:

New Haven, Connecticut 06510
United States

Hari A Deshpande, MD
Phone: 203-200-4622
Email: hari.deshpande@yale.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 27, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.